John Thievon named Dey Pharma president

PITTSBURGH — Mylan's fully integrated specialty pharmaceutical business has a new leader.

The company said it appointed John Thievon as president of Dey Pharma. Prior to joining Dey Pharma, Thievon most recently served as MiddleBrook Pharmaceuticals president and CEO, where he built the company into a 450-person organization before its assets were acquired by Victory Pharma. Additionally, Thievon also worked as EVP commercial operations for Adams Respiratory Therapeutics, where he built the company's marketing platform and led the launch of Mucinex, growing it to a $450 million brand before the company was sold to Reckitt Benckiser.

"I am extremely pleased to welcome John as our new leader of Mylan's specialty business," Mylan president Heather Bresch said. "John's extensive experience growing a branded pharmaceutical business from the ground up and proven track record launching highly successful pharmaceutical brands, like Mucinex, is invaluable as we continue to build on our specialty business. Dey has been and continues to be a very valuable asset and important growth driver for Mylan, evidenced by the strong performance of this business. John's appointment demonstrates our continued commitment to invest in Dey and strengthen what we have in place in order to support the continued success of this business into the future."